Type 1 diabetes results from autoimmune destruction of insulin-producing beta cells, yet many patients retain endogenous beta-cell function several years after clinical onset — some for decades, as evidenced by persistent C-peptide secretion.1 Residual C-peptide secretion has been associated with substantial clinical benefits. For example, data from the Diabetes Control and Complications Trial (DCCT) and the Epidemiology of Diabetes Interventions and Complications follow-up study showed that among DCCT participants who entered the trial within 1 to 5 years after diabetes onset and had a C-peptide response (defined as a mixed meal–stimulated C-peptide peak response of ≥0.2 pmol per milliliter) at . . .
"control" - Google News
September 08, 2022 at 04:01AM
https://ift.tt/14kxUua
CLOuDs Disperse — Top-Notch Glucose Control and Residual C-Peptide Secretion | NEJM - nejm.org
"control" - Google News
https://ift.tt/oPrZLWa
https://ift.tt/GPyCRT1
Bagikan Berita Ini
0 Response to "CLOuDs Disperse — Top-Notch Glucose Control and Residual C-Peptide Secretion | NEJM - nejm.org"
Post a Comment